iShares MDAX® UCITS ETF (DE) CHF is a equity ETF from iShares tracking the MDAX index through physical replication. Domiciled in Germany and launched in 2001, the fund manages about 1.5 bn € and charges a TER of 0.51% — 51 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares MDAX® UCITS ETF (DE) CHF competes with 2 other products on the same index (MDAX): it ranks 1st by fund size and 2nd by ongoing cost, with a TER of 0.51% against a group median of 0.51%. It has been listed since 2001, 25 years of track record — the oldest in its comparison group.
On a €10,000 investment the TER costs 51 € a year. The cheapest of the group is Invesco MDAX® UCITS ETF Acc at 0.19%, or 19 € on the same amount: a difference of 32 € every year, roughly 320 € over ten years before compounding.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 38.7% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in CHF. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Germany, which determines the tax treatment of income received by the fund and the supervisory authority.
| Deutsche Lufthansa AG | 6.1% |
| Knorr-Bremse AG | 4.2% |
| Talanx AG | 4.2% |
| Delivery Hero SE | 4.0% |
| AIXTRON SE | 3.8% |
| Nordex SE | 3.7% |
| Sartorius AG Participating Preferred | 3.7% |
| thyssenkrupp AG | 3.2% |
| Porsche AG | 3.0% |
| Aurubis AG | 2.8% |
| XETRA | EXS3 | EUR |
| Francoforte | EXS3 | EUR |
| SIX Swiss Exchange | MDAXEX | CHF |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.